Associate Professor Eng-Siew Koh

Radiation Oncologist, Liverpool Hospital

COGNO Chair

GCCTI workshop, Sydney
October 27th, 2023

COGNO
COOPERATIVE TRIALS GROUP FOR NEURO-ONCOLOGY

COGNO
COOPERATIVE TRIALS GROUP FOR NEURO-ONCOLOGY

Mission

The achievement of better health outcomes for patients and others affected by brain tumours through clinical trials research

COGNO
COOPERATIVE TRIALS GROUP FOR NEURO-ONCOLOGY

NHMRC Clinical Trials Centre

COGNO-led trials

Established in 2007, since 2010

16 competitive grants
$16+ million
141 AUS study sites
879 participants








NUTMEG (COGNO)

- GBM; ≥ 65 years
- 18 sites
- 102 patients (Aust & USA)
- Actual: 103 patients
- **Status: Follow Up;**
- **Published in *Neurooncology Advances***
- **TR, MRI, PROM sub studies**

CATNON (EORTC)

- Non-1p/19q deleted anaplastic glioma
- 13 sites
- **751 (internationally)**
- **82 patients (Australia)**
- Status: Follow Up

LUMOS 1 (COGNO)

- Grade 2/3 gliomas for molecular profiling
- 5 sites
- 10 patients (Pilot study)
- 10 patients
- Status: Closed out
- TR studies pending

VERTU (COGNO)

- GBM; unmethylated MGMT
- 17 sites
- 125 patients
- 125 patients
- Status: Closing out Sites
- TR, MRI, PROM sub studies

COGNO COOPERATIVE TRIALS GROUP FOR NEURO-ONCOLOGY

Trials in Follow Up

Rich biorepository, linked clinical outcomes

NHMRC Clinical Trials Centre

MAGMA trial in adult Glioblastoma – recruitment & reach

Study lead:
A/ Prof Craig Gedye



COGNO
COOPERATIVE TRIALS GROUP FOR NEURO-ONCOLOGY

MAGMA - The Multi-Arm GliobastoMa Australasia Trial

GBM or glioma with molecular features of GBM

28 sites

Target: 300 patients

Actual: 338 patients



- Largest COGNO-led GBM trial undertaken in Australia to date.
- Recruitment target met - July 2023

TOTAL = 338

- Question 1 - 252
- Question 2 - 291
- Both questions - 205

- **Future for MAGMA – new questions**

Follow up

Sub- studies – Translational Research and PROM

Study lead:
A/ Prof Craig Gedye

Now in Follow Up

Study lead:
Prof Hui Gan

COGNO-led LUMOS2 trial

Low & Anaplastic Grade Glioma **U**mbrella Study of **Mo**lecular Guided Therapie**S**



♣ In-kind support through MoST/CaSP

COGNO COOPERATIVE TRIALS GROUP FOR NEURO-ONCOLOGY

Omico.

Longitudinal samples – initial, re -resection

NHMRC Clinical Trials Centre

LUMOS2 trial – national & international reach

Low & Anaplastic Grade Glioma Umbrella Study of Molecular Guided TherapieS

Timelines	Activity
January 2022	MRFF funding : Arms 1-3 (12 Australian sites)
August 2022	Australian Brain Cancer Mission : Arm 4 funded
October 2022	Grant submission by Canadian Clinical Trials Gp (CCTG) for LUMOS2
Q1, 2023	Breakthrough Grant/ Brain Canada funding successful (12 Canadian sites)
September 2023 October 2023	First Australian site activated; first participant Molecular Tumour Assessment Panel / IDSMC
Q4, 2023 ongoing	Arm 5 and 6 discussions
Q4, 2023/2024 ongoing	Arm 7 …

Brain metastases

National Cancer Institute Collaborative Workshop on Shaping the Landscape of Brain Metastases Research: challenges and recommended priorities

Michelle M Kim, Minesh P Mehta, DeeDee K Smart, Patricia S Steeg, Julie A Hong, Michael G Espey, Pataje G Prasanna, Laura Crandon, Christine Hodgdon, Niki Kozak, Terri S Armstrong, Aki Morikawa, Nicole Willmarth, Kirk Tanner, Adrienne Boire, Melanie Hayden Gephart, Kim A Margolin, Jona Hattangadi-Gluth, Hussein Tawbi, Daniel M Trifiletti, Caroline Chung, Upal Basu-Roy, Robyn Burns, Isabella C Glitza Oliva, Ayal A Aizer, Carey K Anders, Joanne Davis, Manmeet S Ahluwalia, Veronica Chiang, Jing Li, Rupesh Kotecha, Silvia C Formenti, Benjamin M Ellingson, Vinai Gondi, Paul W Sperduto, Jill S Barnholtz-Sloan, Jordi Rodon, Eudocia Q Lee, Mustafa Khasraw, Debra Nana Yeboa, Priscilla K Brastianos, Evanthia Galanis, C Norman Coleman, Mansoor M Ahmed

Lancet Oncol 2023; 24: e344–54



Figure 1: **National Cancer Institute awards (A) and success rates (B) for brain cancer, including brain metastases, for the fiscal years 2018–22**

Brain metastases

Recommendations

- A consensus for reproducible clinical trial endpoints reflective of benefits specific to patients with brain metastases should be developed
- Coalescing behind a national vision to collaboratively conduct a series of coordinated clinical trials will be required for major advances in brain metastases research and treatment

The gap

- Traditional endpoints, such as response rate and survival, inadequately capture what is most meaningful to patients
- Unduly restrictive eligibility for clinical trials and other barriers to access exclude patients from timely access to promising interventions

Priority 4
Optimise the framework for the design and conduct of brain metastases-specific trials

Opportunity
Expanded clinical trial initiatives including innovative and practical basket trials specific to brain metastases could enable assessment of the optimal sequencing of radiotherapy plus drug combinations and accelerate clinical translation to targeted patient populations

Lancet Oncol 2023; 24: e344–54

Thanks and Acknowledgments